Company intelligence / Profile preview

Immodulon Therapeutics

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Immodulon's lead candidate IMM‑101 demonstrated a significant increase in median overall survival when combined with gemcitabine in metastatic pancreatic cancer patients during a randomized clinical trial—a reported improvement of up to 59% over gemcitabine alone. The company was preparing to advance into pivotal trials following positive Phase II data. Its approach leverages innate immune priming via dendritic cell activation and aims to complement standard-of-care therapies without increasing toxicity.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Vaccine (heat-killed whole cell)BiologicImmunomodulator
Industry: Biotech

Drug pipeline

1 asset

IMM-101

Partnerships

Biodesix – collaboration on biomarker discovery using the Diagnostic Cortex machine learning platform for patient selection in pancreatic cancer trials with IMM–101.AIO–Studien–gGmbH – listed as sponsor/collaborator on some studies.

Beyond the preview

Go deeper on Immodulon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immodulon Therapeutics.

Explore the full profile